InVivo Therapeutics Holdings Corp. (NVIV) Officer Receives Prestigious Award
Seeking Alpha Analyst Since 2008
InVivo Therapeutics Holdings Corp. is a medical device company focused on groundbreaking technology for treating spinal cord injuries. The company utilizes polymers as a platform technology to develop treatments to improve function in individuals paralyzed as a result of traumatic spinal cord injury.
The company today announced that its Chief Science Officer Dr. Christopher Pritchard, Ph.D., has been selected as the 2011 recipient of the American Spinal Injury Association’s prestigious Apple Award. The award recognizes excellence in publishing in spinal cord injury research across the globe. This is the fifth year that the Association has presented the Apple award.
Dr. Pritchard and his InVivo Therapeutics team authored the article titled: “Establishing a model spinal cord injury in the African green monkey for the preclinical evaluation of biodegradable polymer scaffolds seeded with human neural stem cells.” The article was published in 2010 in the Journal of Neuroscience Methods.
The award recognizes one of several landmark studies supporting the company’s technology and its brilliant team of scientists led by its Chief Medical Officer, Dr. Edward Woodward, and M.I.T.’s Dr. Robert S. Langer. InVivo’s chief executive officer, Frank Reynolds, was rightly proud of the achievement stating “Acknowledgment of this caliber is an honor and highlights the promise of our strategic initiatives.”
For more information on InVivo Therapeutics, please visit its website at invivotherapeutics.com
Please see disclaimer on QualityStocks website: disclaimer.qualitystocks.net
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.